Sporadic Inclusion Body Myositis (sIBM) - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: SC0D59B23F44EN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Sporadic Inclusion Body Myositis (sIBM) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Sporadic Inclusion Body Myositis (sIBM) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Sporadic Inclusion Body Myositis (sIBM) Understanding

The DelveInsight Sporadic Inclusion Body Myositis (sIBM) epidemiology report gives a thorough understanding of the Sporadic Inclusion Body Myositis (sIBM) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Sporadic Inclusion Body Myositis (sIBM) in the US, Europe, and Japan. The report covers the detailed information of the Sporadic Inclusion Body Myositis (sIBM) epidemiology scenario in seven major countries (US, EU5, and Japan).

Sporadic Inclusion Body Myositis (sIBM) Epidemiology Perspective by DelveInsight

The Sporadic Inclusion Body Myositis (sIBM) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Sporadic Inclusion Body Myositis (sIBM) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Sporadic Inclusion Body Myositis (sIBM) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Sporadic Inclusion Body Myositis (sIBM) Detailed Epidemiology Segmentation

The Sporadic Inclusion Body Myositis (sIBM) epidemiology covered in the report provides historical as well as forecasted Sporadic Inclusion Body Myositis (sIBM) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Sporadic Inclusion Body Myositis (sIBM) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Sporadic Inclusion Body Myositis (sIBM) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Sporadic Inclusion Body Myositis (sIBM) Epidemiology Report and Model provide an overview of the global trends of Sporadic Inclusion Body Myositis (sIBM) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Sporadic Inclusion Body Myositis (sIBM) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Sporadic Inclusion Body Myositis (sIBM)
• The report provides the segmentation of the Sporadic Inclusion Body Myositis (sIBM) epidemiology

Report Highlights

• 11-year Forecast of Sporadic Inclusion Body Myositis (sIBM) epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Sporadic Inclusion Body Myositis (sIBM)
• Cases of Sporadic Inclusion Body Myositis (sIBM) by Mutation Types
• Sporadic Inclusion Body Myositis (sIBM) Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Sporadic Inclusion Body Myositis (sIBM)?
• What are the key findings pertaining to the Sporadic Inclusion Body Myositis (sIBM) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Sporadic Inclusion Body Myositis (sIBM) across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Sporadic Inclusion Body Myositis (sIBM)?
• What are the currently available treatments of Sporadic Inclusion Body Myositis (sIBM)?

Reasons to buy

The Sporadic Inclusion Body Myositis (sIBM) Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Sporadic Inclusion Body Myositis (sIBM) market
• Quantify patient populations in the global Sporadic Inclusion Body Myositis (sIBM) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Sporadic Inclusion Body Myositis (sIBM) therapeutics in each of the markets covered
• Understand the magnitude of Sporadic Inclusion Body Myositis (sIBM) population by its epidemiology
• The Sporadic Inclusion Body Myositis (sIBM) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF SPORADIC INCLUSION BODY MYOSITIS (SIBM)

3. SPORADIC INCLUSION BODY MYOSITIS (SIBM): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Sporadic Inclusion Body Myositis (sIBM) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Sporadic Inclusion Body Myositis (sIBM) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Sporadic Inclusion Body Myositis (sIBM) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Sporadic Inclusion Body Myositis (sIBM) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Sporadic Inclusion Body Myositis (sIBM) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Sporadic Inclusion Body Myositis (sIBM) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Sporadic Inclusion Body Myositis (sIBM) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Sporadic Inclusion Body Myositis (sIBM) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Sporadic Inclusion Body Myositis (sIBM) Treatment and Management
6.2. Sporadic Inclusion Body Myositis (sIBM) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Sporadic Inclusion Body Myositis (sIBM) Epidemiology in 7MM (2019-2032)
Table 2: Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Sporadic Inclusion Body Myositis (sIBM) Epidemiology in the United States (2019-2032)
Table 4: Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Sporadic Inclusion Body Myositis (sIBM) Epidemiology in Germany (2019-2032)
Table 6: Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Sporadic Inclusion Body Myositis (sIBM) Epidemiology in France (2019-2032)
Table 8: Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Sporadic Inclusion Body Myositis (sIBM) Epidemiology in Italy (2019-2032)
Table 10: Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Sporadic Inclusion Body Myositis (sIBM) Epidemiology in Spain (2019-2032)
Table 12: Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Sporadic Inclusion Body Myositis (sIBM) Epidemiology in the United Kingdom (2019-2032)
Table 14: Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Sporadic Inclusion Body Myositis (sIBM) Epidemiology in Japan (2019-2032)
Table 16: Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in 7MM (2019-2032)
Figure 2 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in the United States (2019-2032)
Figure 4 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in Germany (2019-2032)
Figure 6 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in France (2019-2032)
Figure 8 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in Italy (2019-2032)
Figure 10 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in Spain (2019-2032)
Figure 12 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Sporadic Inclusion Body Myositis (sIBM) Epidemiology in Japan (2019-2032)
Figure 16 Sporadic Inclusion Body Myositis (sIBM) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report